• Product nameAnti-BMPR1B antibody
    See all BMPR1B primary antibodies
  • Description
    Mouse monoclonal to BMPR1B
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Recombinant fragment
    Predicted to work with: Human
  • Immunogen

    Recombinant full length protein, corresponding to amino acids 14-503 of Human BMPR1B



Our Abpromise guarantee covers the use of ab54907 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesWB: Use at a concentration of 1-5 µg/ml.

    This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionOn ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP7/OP-1 and GDF5.
    • Involvement in diseaseDefects in BMPR1B are the cause of acromesomelic chondrodysplasia with genital anomalies (AMDGA) [MIM:609441]. Acromesomelic chondrodysplasias are rare hereditary skeletal disorders characterized by short stature, very short limbs, and hand/foot malformations. The severity of limb abnormalities increases from proximal to distal with profoundly affected hands and feet showing brachydactyly and/or rudimentary fingers (knob-like fingers).
      Defects in BMPR1B are a cause of brachydactyly type A2 (BDA2) [MIM:112600]. Brachydactylies (BDs) are a group of inherited malformations characterized by shortening of the digits due to abnormal development of the phalanges and/or the metacarpals. They have been classified on an anatomic and genetic basis into five groups, A to E, including three subgroups (A1 to A3) that usually manifest as autosomal dominant traits. BDA2 was described first in a large Norwegian kindred. BDA2 is caused by mutations in BMPR1B gene and studies demonstrate that these mutations function as dominant negatives in vitro and in vivo.
    • Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
      Contains 1 GS domain.
      Contains 1 protein kinase domain.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Activin receptor like kinase 6 antibody
      • Acvrlk6 antibody
      • ALK 6 antibody
      • ALK6 antibody
      • alk6tr antibody
      • BMP type-1B receptor antibody
      • BMPR IB antibody
      • BMPR-1B antibody
      • Bmpr1b antibody
      • BMPRIB antibody
      • BMR1B_HUMAN antibody
      • Bone morphogenetic protein receptor type 1B antibody
      • Bone morphogenetic protein receptor type IB antibody
      • Bone morphogenetic protein receptor type-1B antibody
      • BR 1b antibody
      • BR1b antibody
      • CDw 293 antibody
      • CDw293 antibody
      • CDw293 antigen antibody
      • CFK 43a antibody
      • CFK43a antibody
      • Serine/threonine receptor kinase antibody
      • zALK 6 antibody
      • zALK6 antibody
      see all

    Anti-BMPR1B antibody images

    • Western blot against tagged recombinant protein immunogen using ab54907 BMPR1B antibody at 1ug/ml. Predicted band size of immunogen is 80 kDa.

      This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

    References for Anti-BMPR1B antibody (ab54907)

    ab54907 has not yet been referenced specifically in any publications.

    Product Wall

    Application Western blot
    Sample Rat Tissue lysate - whole (rat aorta)
    Loading amount 40 µg
    Specification rat aorta
    Gel Running Conditions Reduced Denaturing (9% SDS-PAGE)
    Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

    Dr. Chrispina Hong

    Verified customer

    Submitted Jan 21 2013